The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W   Bertoni John M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease: A Review of Symptomatic and Potential Disease-Modifying Effects

By Schapira Anthony H.V.  

CNS Drugs, Vol. 25, Iss. 12, 2011-12 ,pp. : 1061-1071

Adis International

Access to resources Recommend Favorite

Community and Long-Term Care Management of Parkinson's Disease in the Elderly: Focus on Monoamine Oxidase Type B Inhibitors

By Chen Jack J.  

Drugs & Aging, Vol. 24, Iss. 8, 2007-01 ,pp. : 663-680

Adis International

Access to resources Recommend Favorite

Monoamine oxidase A and B inhibitors

By Jegham S.   George P.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1143-1150

Informa Healthcare

Access to resources Recommend Favorite

Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-01 ,pp. : 777-785

Bentham Science Publishers

Access to resources Recommend Favorite